openPR Logo
Press release

Transforming Mental Health Treatments and Expanding Clinic Networks: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)

01-23-2025 11:56 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: CAP, LLC
Transforming Mental Health Treatments and Expanding Clinic

Image: https://www.globalnewslines.com/uploads/2025/01/1737669812.jpg

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP), a clinical-stage biopharmaceutical leader, is at the forefront of addressing critical mental health challenges, including suicidal depression, bipolar disorder, and PTSD. Through groundbreaking therapeutics and strategic investments, the company aims to revolutionize care for millions while delivering significant returns for investors.

A Breakthrough in Mental Health Treatment

NRX-101, the company's flagship product, is an FDA-designated investigational Breakthrough Therapy targeting suicidal treatment-resistant bipolar depression and chronic pain. If approved, it will become the first FDA-approved medication specifically for suicidal depression. Designed to meet the needs of over 13 million Americans who seriously consider suicide annually, NRX-101 offers hope to a market valued at $3-5 billion.

Additionally, NRx is developing NRX-100, an intravenous ketamine therapy for suicidal depression. Ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, yet there is no FDA-labeled product currently available. NRx's New Drug Application (NDA) for NRX-100, supported by robust data from NIH and European trials, marks a pivotal step toward addressing this unmet need.

Strategic Partnerships and Expanding Operations

NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101. Beyond its mental health applications, NRX-101 shows promise as a non-opioid chronic pain treatment and as a therapy for complicated urinary tract infections (UTIs).

The company recently signed a binding term sheet with Smith & Sauer, LLC, securing $27 million in funding. This capital will drive the expansion of HOPE Clinics, an international network of interventional psychiatry facilities, and advance the regulatory applications for NRX-100 and NRX-101. Key details of the funding agreement include:

* $25 million for equity purchases in HOPE Therapeutics, a subsidiary focused on clinic acquisitions.
* $2 million for advancing new drug applications.
* Investor-friendly terms, including preferred stock and warrants with attractive returns.

Kadima Neuropsychiatry Institute: A Flagship Acquisition

As part of its strategic growth, NRx is acquiring the Kadima Neuropsychiatry Institute in La Jolla, CA. Kadima, renowned for pioneering ketamine therapy, offers cutting-edge treatments for conditions such as depression, PTSD, and anxiety. With established contracts with the Department of Veterans Affairs and the Department of Defense, Kadima's expertise and robust research capabilities will enhance HOPE's operations.

Kadima's founder, Dr. David Feifel, a global leader in advanced interventional psychiatry, will join NRx as Chief Medical Innovation Officer, driving innovation and clinical trials for CNS disorders. This acquisition solidifies HOPE Clinics' position as a leader in delivering advanced psychiatric care.

Investor Highlights

NRx Pharmaceuticals (NASDAQ: NRXP) has earned a $31 price target from D. Boral Capital, reflecting confidence in the success of its products and clinic network expansion. This valuation accounts for:

* Revenue from NRX-100 and NRX-101.
* Profits from HOPE Clinic operations.
* Conservative risk-adjusted models with significant growth potential.

Key Milestones Ahead

With the completion of the NDA filing for NRX-100 expected in Q1 2025, NRx is poised for rapid regulatory and market advancements. Additionally, the company will present at the J.P. Morgan Healthcare Conference, offering an opportunity to engage with investors and highlight its transformative vision.

Why Invest in NRx Pharmaceuticals?

NRXP is uniquely positioned to address the urgent mental health crisis with innovative therapies and a robust clinic network. The company's strategic partnerships, clinical milestones, and investor-focused funding model create a compelling growth narrative for stakeholders. As the demand for effective mental health treatments grows, NRx Pharmaceuticals stands out as a leader in innovation and impact.

For more information on NRXP: https://www.nrxpharma.com/

DISCLAIMER: https://corporateads.com/disclaimer/ [about:blank]

Disclosure listed on the CorporateAds website
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: Send Email [http://www.universalpressrelease.com/?pr=transforming-mental-health-treatments-and-expanding-clinic-networks-nrx-pharmaceuticals-inc-stock-symbol-nrxp]
Phone: 484 254 6134
Address:1201 Orange Street Suite 600
City: Miami
State: Florida
Country: United States
Website: https://www.nrxpharma.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Transforming Mental Health Treatments and Expanding Clinic Networks: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) here

News-ID: 3830839 • Views:

More Releases from Getnews

Nomad Fuel Launches Next-Generation Platform to Revolutionize Fleet Management Across North America
Nomad Fuel Launches Next-Generation Platform to Revolutionize Fleet Management A …
Nomad Fuel, a rising force in Canada's freight tech industry, announces the launch of its new fuel management product, a fully modernized and rebuilt platform redefining how trucking fleets buy, manage, and optimize their fuel spend. Image: https://www.globalnewslines.com/uploads/2025/09/26ac068f61b46617b59c516c32ebb47f.jpg For decades, fuel management has lagged behind other innovations in the transportation industry. The way fleets purchase, track, and optimize fuel spend has remained clunky, outdated, and shrouded in mystery. The new platform is
Actionable Security Launches Salesforce Security Risk Assessment to Help Businesses Defend Against Rising Cyber Threats
Actionable Security Launches Salesforce Security Risk Assessment to Help Busines …
Actionable Security today announced the launch of its Salesforce Security Risk Assessment, a new service designed to help businesses safeguard sensitive customer data and maintain operational continuity in the face of growing cyber threats. As part of Actionable Security's broader suite of cybersecurity offerings, the assessment provides organizations with a clear, actionable roadmap to harden their Salesforce environments against attack. Salesforce has become a cornerstone platform for industries such as healthcare,
Casteel Chiropractic of State College, P.C. Expands Access to Advanced Chiropractic Care
Casteel Chiropractic of State College, P.C. Expands Access to Advanced Chiroprac …
Image: https://www.globalnewslines.com/uploads/2025/10/1759510218.jpg Casteel Chiropractic of State College, P.C. continues to provide trusted care for individuals seeking relief from pain and improved wellness. Known for its patient-focused approach, the practice has become a leading choice for those searching for a Chiropractor State College. With a commitment to evidence-based methods, the clinic emphasizes safe, effective, and personalized care designed to restore balance and function to the body. One of the core services offered at
Toronto Commercial Refrigeration Sees Strong Customer Uptake of New Nationwide Shipping Checkout Tool
Toronto Commercial Refrigeration Sees Strong Customer Uptake of New Nationwide S …
Toronto Commercial Refrigeration, a Canadian supplier of brand-new commercial refrigeration equipment, announced today that its newly launched in-cart freight calculator is already showing significant results, with especially strong adoption from customers across Ontario, Quebec, and Manitoba. Image: https://www.globalnewslines.com/uploads/2025/09/162ba453aeecd4b22b877369937cd61e.jpg Since its introduction earlier this summer, the feature has streamlined the buying process by providing customers with instant, transparent shipping quotes directly in the online checkout. Early data shows that foodservice operators, retailers, and

All 5 Releases


More Releases for NRx

$40 Price Target in New H. C. Wainright Analyst Report on Leader in $3 Billion S …
Image: https://www.globalnewslines.com/uploads/2025/09/1757392285.jpg $NRXP Continues Expansion with Completion of Dura Medical Acquisition in Network of Interventional Psychiatry Clinics * Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. * Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). * H.C. Wainright Analyst Report Cites Paradigm Shift in the Treatment of Depression With Suicidality; Assuming Coverage
Advancements on Multiple Fronts in $3 Billion Suicidal Depression Market, Highli …
Image: https://www.globalnewslines.com/uploads/2025/08/1755525181.jpg $NRXP Sees 10-Fold Market Expansion to 13 Million Americans for Bipolar Depression Alone. * Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. * Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). * FDA Fast Track Designation for NRX 100 for Suicidal Ideation in Patients with Depression, Including Bipolar Depression.
$3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track …
Image: https://www.globalnewslines.com/uploads/2025/08/1754917343.jpg $NRXP Has $7.8 Million for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD * Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. * Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). * FDA Fast Track Designation for NRX
$300 Million in Milestones Plus Tiered Double-Digit Royalties from Accepted Term …
Image: https://www.globalnewslines.com/uploads/2025/03/1742217317.jpg $NRXP is Poised to Address Over $3 Billion Suicidal Depression Market in the US * Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. * Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression * Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). * New Drug Application for
NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant's Efficacy in Re …
- Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD. - June Meeting of the American Society for Clinical Psychopharmacology Focused on Intravenous Ketamine and Intranasal S-Ketamine for Severe Depression and Suicidality. - Presenters from 3 Open Label Studies at the ASCP Suggested Intravenous Ketamine is Equivalent or has Advantages over Intranasal S-Ketamine. - NRXP Reached 9-Month Stability Point with its Ketamine Formulation (NRX-100) and Initiated
Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plan …
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD. MOU Signed with Conversio Health with Immediate Plans to Ship IV Ketamine Product to Full Range of Customers via 503a and 503b Pharmacies. Clinical Trial Success in Proving a Statistically-Significant 76% Reduction in Akathisia in Participants Treated with NRX-101 Compared to Lurasidone. Company Plans to Seek Accelerated Approval of NRX-101 for Bipolar Depression and Akathisia and Broaden